放射性碘治疗对分化型甲状腺癌患者健康相关生活质量影响的系统综述与荟萃分析
该研究系统检索2000年至2026年6月间评估分化型甲状腺癌(DTC)患者接受放射性碘治疗(RIT)后健康相关生活质量(HRQoL)的观察性研究与随机对照试验,共纳入53项研究(6项进入荟萃分析)。结果显示RIT前后HRQoL已受损,治疗后数月多数患者较基线改善,一年后接近一般人群水平,但部分症状可持续存在且严重程度与剂量相关。
要点
- RIT前DTC患者HRQoL已低于一般人群,治疗前后均需关注。
- RIT后数月多数患者HRQoL较基线改善,一年后接近一般人群。
- 部分患者RIT相关症状持续存在,严重程度与接受剂量有关。
核心结论
- RIT相关症状或焦虑可能在治疗前后损害HRQoL。
- HRQoL随时间趋于接近一般人群水平,但并非所有患者均能达到同等水平。
- 部分患者可能持续存在症状,其严重程度取决于接受的剂量。
- 结果异质性提示未来需采用更同质且甲状腺特异性的问卷,并纳入对给药活度和准备方法等混杂因素的校正分析及术前评估。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南报告。
- 检索PubMed、Scopus、Web of Science和Cochrane数据库,时间范围为2000年1月至2026年6月。
- 纳入评估DTC患者接受RIT后HRQoL的观察性研究和随机对照试验。
- 系统综述共纳入53项研究,其中6项纳入荟萃分析。
- 观察性研究采用纽卡斯尔-渥太华量表评估方法学质量与偏倚风险,随机试验采用Cochrane偏倚风险2工具。
主要发现
- RIT给药前,患者HRQoL已较一般人群受损。
- RIT后某些症状的出现有时对HRQoL产生负面影响。
- 治疗后数月,多数患者HRQoL较基线总体改善。
- 治疗后一年以上,HRQoL接近一般人群水平。
- 部分患者可能持续存在症状,其严重程度取决于接受的剂量。
临床怎么用
- 临床应关注DTC患者RIT前后的HRQoL,尤其是治疗前后的症状与焦虑管理。
- 对低复发风险患者考虑RIT时,需权衡其对HRQoL的短期影响与长期获益。
- RIT后持续症状的严重程度与剂量相关,个体化评估给药活度可能有助于减少HRQoL损害。
局限性
- 纳入研究结果存在异质性。
- 未来需采用更同质且甲状腺特异性的问卷。
- 未来需纳入对给药活度和准备方法等混杂因素的校正分析及术前评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of differentiated thyroid carcinoma (DTC) has markedly increased since the 1990s. The patients' health-related quality of life (HRQoL) is an essential outcome to consider, both short- and long-term. After thyroidectomy, treatment generally includes radioiodine therapy (RIT), the impact of which on HRQoL remains debated, particularly in patients at low risk of recurrence. This systematic review with meta-analysis aims to comprehensively evaluate the association of RIT with HRQoL in patients with DTC throughout the disease trajectory. METHODS: A systematic literature review was conducted, and the findings are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Scopus, Web of Science, and Cochrane databases were searched for studies published between January 2000 and June 2026. Observational studies and randomized controlled trials assessing HRQoL in patients with DTC treated with RIT were eligible for inclusion. Methodological quality and risk of bias were assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias 2 tool for randomized trials. Random-effects meta-analyses were performed when the data allowed. RESULTS: In total, 53 studies were included in the systematic review, of which 6 were included in the meta-analyses. Before the administration of RIT, patients' HRQoL was already impaired compared with that of the general population. After RIT, the onset of certain symptoms had sometimes a negative impact on HRQoL. Few months post treatment, an overall improvement in HRQoL was observed in most patients compared with baseline. More than one year post treatment, HRQoL approach is that of the general population. CONCLUSIONS: Symptoms or anxiety associated with RIT may impair HRQoL around the time of treatment. HRQoL tends to approach that of the general population, although it does not consistently reach the same level. Furthermore, some patients may continue to experience persistent symptoms whose severity depends on the dose received. The heterogeneity of the results highlights the importance of future studies using more homogeneous and thyroid-specific questionnaires, and to include analyses adjusted for confounding factors such as administered activity and preparation methods, along with a pre-surgical assessment, in order to better evaluate the specific effect of RIT on HRQoL.
引用
- Bondet de La Bernardie S, Lussey-Lepoutre C, Buffet C, et al. The Effects of Radioiodine Treatment on Health-Related Quality of Life in Patients Treated for a Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Thyroid. 2026. PMID: 42975204. doi:10.1177/10507256261499230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。